Navigation Links
Compound stymies polyomaviruses in lab tests
Date:11/13/2013

A team of scientists reports that a small molecule compound showed significant success in controlling the infectivity and spread of three polyomaviruses in human cell cultures. To date there has been no medicine approved to treat such viruses, which prey on transplant recipients, people with HIV, and others whose immune systems have been weakened.

The compound, known by the abbreviated name "Retro-2," was able to protect the vast majority of cells in cultures when it was administered even after infection began. According to results published this week in the journal mBio, 12 days of treatment with Retro-2 kept 90.5 percent of cells free from JC Polyomavirus, 89 percent of cells clear of the BK Polyomavirus, and 84 percent of cells protected from the SV40 polyomavirus. Infection rates and virus production were much higher among cells in cultures that were similarly infected, but left untreated as controls.

That the compound gained the upper hand on viruses that had a head start is a key advance, said Brown University biologist Walter Atwood, corresponding author of the paper. Other substances have defeated the viruses only if they were used to pre-treat cells before any infection.

"But that's not reality," Atwood said. "The reality is that someone is already infected with the virus. Whenever in the past we first infected the cells with the virus and then came in with the drug, we've never been successful in being able to stop the spread of the virus. This drug is successful at that."

Brown University has a patent filed on the use of the compound against pathogen infections. The research also involved a team of scientists at Yale University led by Professor Daniel DiMaio.

An 'ER' medicine

Retro-2 appears to work by blocking the ability of polyomaviruses to sneak around host cells by hijacking the workings of the intracellular protein transportation hub: the endoplasmic reticulum (ER).

Christian Nelson, a Brown postdoctoral researcher currently visiting at Yale, first thought to study Retro-2 after reading a 2010 paper in Cell showing that it blocks certain toxins, including ricin, from working through the ER. Ricin and polyomaviruses have been thought to operate similarly. The compound also did not appear to be toxic to the mice in that study.

"There are a lot of viruses that use these trafficking mechanisms," Atwood said.

So the team bought some Retro-2 from Chembridge, a company that makes vast libraries of small molecule compounds for scientists to study, and pitted it against the polyomaviruses.

The researchers tested it in several ways, including with both kidney cells and brain cells because those are the tissues in the body where they can cause disease. Retro-2 appeared effective in protecting the various cells, as long as it was present within several hours of infection.

"When this causes disease in people there's progressively more and more cells infected," Nelson said. "If we can identify infection early, a treatment could help to stop that progression."

Improving the chemistry

Atwood and Nelson acknowledge that they aren't yet sure exactly how Retro-2 blocks the viruses in the ER, but thanks to a team of collaborating chemists, they do know what chemical structure makes the drug effective.

Brown chemistry Professors Jason Sello and Paul Williard and graduate student Daniel Carney studied the compound's chemical structure. In efforts to prepare Retro-2, Sello and Carney found that the last step in the synthesis yielded not only the reported structure but also a form called a dihydroquinazolinone (DHQ). The DHQ was the apparent result of a "cyclizing" reaction of Retro-2 that gives it a different chemical structure.

Further experiments identified the exact structure of the DHQ form and showed that it was the form that matched what Atwood and Nelson had found to be effective in the lab.

This detailed understanding of the compound is helping Sello and his team improve the drug further.

"A critical part of any drug development program is the unambiguous assignment of the structure of the lead compound," Sello said. "With knowledge of the Retro-2 structure, we have been rationally preparing analogs that have improved pharmacological properties."


'/>"/>

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert  

Related biology news :

1. Canadian girl, 16, invents disease-fighting, anti-aging compound using tree particles
2. Biosensor illuminates compounds to aid fight against TB
3. New screening technique yields elusive compounds to block immune-regulating enzyme
4. Sulphur and iron compounds common in old shipwrecks
5. Heparin-like compounds inhibit breast cancer metastasis to bone
6. Like curry? New biological role identified for compound used in ancient medicine
7. Nuisance seaweed found to produce compounds with biomedical potential
8. Dont feel like exercise? Scientists find compound that may help you work out harder
9. New drug-screening method yields long-sought anti-HIV compounds
10. Nonstoichiometric Compounds V - An ECI Conference Series
11. New compound holds promise for treating Duchenne MD, other inherited diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Compound stymies polyomaviruses in lab tests
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology: